Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
48 hedge funds and large institutions have $79.4M invested in Genocea Biosciences, Inc. in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 14 closing their positions.
21% more capital invested
Capital invested by funds: $65.7M → $79.4M (+$13.7M)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less funds holding
Funds holding: 57 → 48 (-9)
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $25K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$3.35M |
| 2 |
EMG
Ellington Management Group
Old Greenwich,
Connecticut
|
+$191K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$147K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$145K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$3.19M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$490K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$334K |
| 4 |
Millennium Management
New York
|
-$320K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$236K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
51
Credit Suisse
Zurich,
Switzerland
| – | -$236K | -7,208 | Closed |
|
52
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$213K | -6,503 | Closed |
|
53
Squarepoint
New York
| – | -$176K | -5,363 | Closed |
|
|
AGM
54
Alpine Global Management
New York
| – | -$120K | -3,646 | Closed |
|
|
LP
55
LMR Partners
London,
United Kingdom
| – | -$91K | -2,766 | Closed |
|
|
PA
56
Perceptive Advisors
New York
| – | -$71K | -2,164 | Closed |
|
57
Balyasny Asset Management
Chicago,
Illinois
| – | -$44K | -1,349 | Closed |
|
58
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$41K | -1,250 | Closed |
|
|
IA
59
IFP Advisors
Tampa,
Florida
| – | -$29K | -875 | Closed |
|
60
Barclays
London,
United Kingdom
| – | -$9K | -264 | Closed |
|
61
Acadian Asset Management
Boston,
Massachusetts
| – | -$4K | -111 | Closed |
|
GNCA Hedge Fund Activity: Q3 2016 in Review
48 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q3 2016, worth a combined $79.4M — up 21% from $65.7M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of GNCA and 5 opened new positions — a net loss of 9 holders — while 14 trimmed existing stakes and 15 added.
The largest buyer was Northpointe Capital, adding an estimated $3.35M. The largest seller was AWM Investment Company, exiting entirely with an estimated $3.19M sold.
- 48 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q3 2016, down from 57 in Q2 2016.
- Funds reported $79.4M of Genocea Biosciences, Inc. stock for Q3 2016, up 21% quarter-over-quarter.
- 5 funds opened new Genocea Biosciences, Inc. positions in Q3 2016 and 14 closed out, a net change of -9 holders.
- The largest Genocea Biosciences, Inc. buyer in Q3 2016 was Northpointe Capital, an estimated $3.35M added.
- The largest Genocea Biosciences, Inc. seller in Q3 2016 was AWM Investment Company, an estimated $3.19M sold.
Based on aggregated 13F filings for Q3 2016.